Bridging Innovation. Transforming Care. For Japanese Patients.
Too many breakthrough medicines never reach Japan. We make sure they do.
Our Mission
Unlocking Global Therapies for Japanese Patients
At DLR Pharma, our name stands for Drug Loss Resolution—a commitment to closing the gap in drug availability between Japan and the world.
Every year, groundbreaking medicines are approved around the world—but many never reach Japan. For example, between 2016 and 2020, over 140 innovative therapies were approved in the U.S. and Europe but remained unavailable in Japan by the end of 2022. Of these, more than 60% — especially orphan, pediatric, and start-up originated drugs—which address serious and rare conditions, yet have not even begun clinical development in Japan.
We believe Japanese patients deserve access to the best global treatments.
Our mission is to identify, license, and develop these high-potential therapies for the Japanese market, helping to resolve unmet medical needs and bring hope to those facing intractable diseases.
Our Approach
From Global Innovation to Local Impact
DLR Pharma transforms promising global therapies into real-world solutions for Japanese patients through a streamlined, strategic process. Our integrated model makes it possible for international biotechs and pharma companies to bring therapies to Japan without the usual barriers: